Home / Street Sector / Stocks to Must have in Portfolio- Juno Therapeutics Inc. (NASDAQ:JUNO), Thermo Fisher Scientific, Inc. (NYSE:TMO)

Stocks to Must have in Portfolio- Juno Therapeutics Inc. (NASDAQ:JUNO), Thermo Fisher Scientific, Inc. (NYSE:TMO)

Juno Therapeutics Inc. (NASDAQ:JUNO) runs in leading trade, it knocking up 12.72% to traded at $33.42. JUNO attains analyst recommendation of 2.20 on scale of 1-5 with week’s performance of 12.34%.

Novartis AG (ADR) (NYSE: NVS) and Juno Therapeutics Inc (NASDAQ: JUNO)  are working for a breakthrough in the novel treatment methodology. Juno, which is developing a CAR-T therapy for lymphoblastic leukemia, was forced to modify its trial following halting of the trial in June in the wake of deaths of several trial participants. The firm reasoned that the deaths were due to neurotoxicity resulting from chemo agent fludarabine used in the CAR-T pre-conditioning regimen. Consequently, the firm was forced to push back the target launch date to the first half of 2018 from 2017.

To find out the technical position of JUNO, it holds price to book ratio of 2.92 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. JUNO is presenting price to cash flow of 3.69.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 28.30%, and looking further price to next year’s EPS is -6.50%. While take a short look on price to sales ratio, that was 82.02.

Thermo Fisher Scientific, Inc. (NYSE:TMO) kept active in under and overvalue discussion, TMO holds price to book ratio of 2.94 that presents much better indicator to find market price of a share price over its book value of equity for investment valuation. In addition, the firm has price to earnings ratio of 31.74, which is authentic method to judge but not universal for all situation.

Fundament/ News Factor in Focus

Taking look on ratio analysis, TMO has forward price to earnings ratio of 17.14, compare to its price to earnings ratio of 31.74. Adding one more ration to find detail valuation of security, price to earnings growth ration that stands at 2.93.  The firm has price volatility of 1.54% for a week and 1.47% for a month. Its beta stands at 0.97 times. Narrow down four to firm performance, its weekly performance was 4.79% and monthly performance was 4.39%.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Check Also

Stocks Luring Investors Focus: General Growth Properties, Inc (NYSE:GGP), Spirit Realty Capital, Inc. (NYSE:SRC)

Under investment valuation analysis, General Growth Properties, Inc (NYSE:GGP) presented as an active mover, it …

Leave a Reply

Your email address will not be published. Required fields are marked *